
Pizza
Share
Author: Svetlana Velhush

Pizza
In 2026, the line between the pharmacy and the supermarket has finally blurred.
April 2026 will go down in history as the month when grocery retail officially recognized: we no longer eat to satisfy hunger. We eat to comply with biochemical protocols.
The explosive growth in the popularity of GLP-1 drugs (semaglutide and its analogs) has created a unique market demand. When your appetite is physiologically limited to 800–1000 calories a day, every bite must be "golden." The industry responded by creating Companion Foods — lines with extremely high leucine content (to prevent sarcopenia) and chelated forms of minerals. This is food for those who "forget to eat" but want to maintain muscle and glowing skin.
The "mushroom renaissance" in coffee shops is not just a fad for the exotic. Adding Lion's Mane extract to a morning drink has become a social marker of an "optimizer." We have moved from simple stimulation of the nervous system with caffeine to attempts at its repair and upgrade. As biochemist Rhonda Patrick notes, today food is a way of modulating gene expression and supporting neuroplasticity.
The main innovation of the year is the linking of your tracker ring or watch with a delivery app. If your gadget records poor sleep and a cortisol spike in the morning, the algorithm will automatically suggest a breakfast with increased magnesium and slow carbohydrates. This is the end of the "intuitive eating" era and the beginning of the era of the algorithmic nutritionist.
In the long run, this leads to even greater social stratification: between those who can afford "smart food" and those who remain within the traditional mass market. Will personalized nutrition become a basic human right or remain elite biohacking? The answer to this question will shape the face of healthcare by 2030.
Bloomberg Health — аналитический отчет о влиянии GLP-1 на доходы пищевых гигантов (Nestle, Danone).